Clinical Trials on Leukemia, B-Cell, Chronic

Total 7809 results

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Leukemia

United States
Bristol-Myers Squibb

Completed

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Follicular Lymphoma | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Diffuse Large B-Cell Leukemia

United States
Zhejiang DTRM Biopharma

Completed

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

Chronic Lymphocytic Leukemia | B-Cell Lymphoma

United States
University of Miami
AstraZeneca

Terminated

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Small Lymphocytic Leukemia

United States
AbbVie

Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | B Cell Malignancies

United States, Israel, Australia, France, United Kingdom, Belgium, Spain
Fate Therapeutics

Recruiting

FT819 in Subjects With B-cell Malignancies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | Precursor B-Cell Acute Lymphoblastic Leukemia

United States
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

B Cell Lymphoma | B Cell Leukemia

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Uppsala University
Karolinska University Hospital; Uppsala University Hospital; AFA Insurance; Swedish...

Completed

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

B Cell Lymphoma | B Cell Leukemia

Sweden
Chinese PLA General Hospital

Unknown

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Ångstrom Pharmaceuticals

Terminated

Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | SLL

United States
University Hospital Heidelberg

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, Adult

Germany
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia | Refractory | Relapsed

China
AbbVie
F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer...

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

Chronic Lymphocytic Leukemia (CLL)

United States, Australia, Austria, Bulgaria, Germany, Italy, Spain, Israel, Brazil, Romania
AbbVie

Completed

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation (FORTE)

Cancer | Chronic Lymphocytic Leukemia (CLL)

Russian Federation
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Nanfang Hospital of Southern Medical University

Recruiting

Induced-T Cell Like NK Cells for B Cell Malignancies

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | B Cell Leukemia | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia. (CLL0911)

B-cell Lymphoid Leukemia | Young Patients

Italy
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
Carevive Systems, Inc.

Completed

Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study

CLL

United States
M.D. Anderson Cancer Center
Celgene

Completed

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL

United States
University Hospital, Clermont-Ferrand

Recruiting

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia (RAVEN)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | CLL | Relapsed Chronic Lymphocytic Leukemia | Progressive Chronic Lymphocytic Leukemia

France
Alexion Pharmaceuticals

Terminated

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Multiple Myeloma | B-cell Chronic Lymphocytic Leukemia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

Lymphoma | B-cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
University of California, San Diego
Celgene Corporation

Completed

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | CLL

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditions

United States
Novartis Pharmaceuticals

Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | Large B-cell Lymphoma

Japan, Australia, Germany, Italy, Spain, France, Austria, United States
Xuzhou Medical University

Recruiting

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small Lymphocytic | CLL | SLL | Small-Cell Lymphoma | Leukemia, Chronic Lymphocytic

Italy, Argentina, Chile, Brazil, Israel, South Africa, United States, Australia, Puerto Rico, Spain, Canada, Germany, France, United Kingdom, Colombia
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
University of Milano Bicocca

Recruiting

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.

Mantle-cell Lymphoma | B Cell Chronic Lymphocytic Leukemia

Italy
French Innovative Leukemia Organisation
AbbVie; AstraZeneca; BeiGene; Janssen-Cilag Ltd.

Recruiting

French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings (FOLLOW)

CLL/SLL

France
German CLL Study Group
Cancer Trials Ireland; Stichting Hemato-Oncologie voor Volwassenen Nederland... and other collaborators

Active, not recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)

Chronic Lymphoid Leukemia

Spain, Ireland, Austria, Denmark, Israel, Norway, Germany, Switzerland, Italy, Belgium, Finland, Sweden, Netherlands
AbbVie

Completed

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia) (VENCLL regPMOS)

Cancer | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

Japan
Ohio State University Comprehensive Cancer Center
Amgen

Completed

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Hematopoietic/Lymphoid Cancer | Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Kami Maddocks, MD

Active, not recruiting

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory/Relapsed Chronic Lymphocytic Leukemia

United States
AstraZeneca

Recruiting

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Japan
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Chronic Lymphocytic Leukemia (CLL) | Cutaneous T-cell Lymphoma (CTCL) | Mycosis Fungoides (MF) | Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype | Adult T-Cell Leukemia/Lymphoma (ATLL)

United States
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B Chronic Lymphocytic Leukemia

United States
AstraZeneca
UKCLL Forum

Recruiting

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom (EPIC)

Chronic Lymphocytic Leukemia, CLL

United Kingdom
Novartis Pharmaceuticals

Terminated

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Chronic Lymphocytic Leukemia (CLL)

United States
Medical College of Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Central Nervous System Lymphoma | Mantle Cell Lymphoma (MCL) | Non Hodgkin Lymphoma (NHL)

United States
AbbVie

Completed

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Genzyme, a Sanofi Company

Completed

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States

Clinical Trials on Leukemia, B-Cell, Chronic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations